OOIR: Observatory of International Research

Papers

(The TQCC of Experimental Hematology & Oncology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms	262
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity	199
Inhibition of EYA family tyrosine phosphatase activity reveals a therapeutic vulnerability and enhances Menin and DOT1L inhibitor efficacy in KMT2A-rearranged leukemia	164
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	145
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	134
Tertiary lymphoid structures correlate with reduced recurrence risk and enhanced antitumor immunity in esophageal squamous cell carcinoma with pathologic non-complete response to neoadjuvant chemoimmu	131
Correction: The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma	117
Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy	112
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	107
From Amphiphiles to mRNA platforms: emerging vaccination strategies for pancreatic cancer	106
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	93
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	92
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	91
MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting	89
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	88
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	85
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	79
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	77
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	75
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	74
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	69
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	69
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	67
Tetrahydromagnolol targets TRIM38 to mediate PANoptosis in cancer cells and has the potential for synergistic cancer therapy	67
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	65

All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	64
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	63
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	63
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	58
Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting	57
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	57
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	56
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	54
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	54
Breast cancer heterogeneity and its implication in personalized precision therapy	52
Role of m6A writers, erasers and readers in cancer	51
Three-dimensional chromatin landscapes in MLLr AML	50
The novel retinoid WYC-209 sensitizes multiple myeloma to carfilzomib via epigenetically upregulating ZMYND8	50
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	50
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma	48
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	47
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	45
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	44
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells	42
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma	41
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity	41
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma	41
TCR engineered T cells for solid tumor immunotherapy	40
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination	39
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response	38
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia	38
Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells	38
Matrix stiffness induces Ca2+-DCLK1-PIP5K1A mechanotransduction as a context-specific amplifier in pancreatic cancer progression and chemotherapy resistance	37
Correction: Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	37
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma	37
Metabolic drivers of genome instability in cancer: mechanisms and therapeutic opportunities	36
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances	36
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes	36
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis	35
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs	35
Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study	34
Hepatitis B surface antigen: carcinogenesis mechanisms and clinical implications in hepatocellular carcinoma	34
Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11bhighCD27low memory-like NK cells	34
Preclinical investigations and a first-in-human phase 1a trial of JS007, a novel anti-CTLA-4 antibody, in patients with advanced solid tumors	34
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma	34
The clinical impact of IKZF1 mutation in acute myeloid leukemia	33
Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy	33
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation	33
A one-base therapeutic insertion in the HBG2 distal promoter reactivates γ-globin expression	33
KMT2A alterations in acute myeloid leukemia: a proposed genetic risk model and transplantation outcomes	33
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model	32
Immunotherapy in breast cancer: current landscape and emerging trends	32
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential	32
Crosstalk between O-GlcNAcylation and ubiquitination: a novel strategy for overcoming cancer therapeutic resistance	31
Disparities in the incidence, mortality and disability-adjusted life years of 33 early-onset cancer groups globally, 2012–2021: a systematic analysis	31

Antibody-drug conjugates in breast cancer: current evidence and future directions	31
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review	31
Recent advances and future perspectives in the therapeutics of prostate cancer	29
Versatile function of NF-ĸB in inflammation and cancer	29
New exploration of KRASG12D inhibitors and the mechanisms of resistance	29
Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights	29
Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder	28
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma	28
Downregulation of pro-surfactant protein B contributes to the recurrence of early-stage non-small cell lung cancer by activating PGK1-mediated Akt signaling	28
Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy	28
Decoding the spatiotemporal characteristics of ferroptosis: reshaping tumour therapeutic strategies	27
FGL1-mediated lymph node metastasis in stage T1 non-small cell lung cancer: therapeutic targeting	27
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma	27
The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity	27
Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study	27
Antitumor effect of a small-molecule inhibitor of KRASG12D in xenograft models of mucinous appendicular neoplasms	27
Validation of a microRNA profile in urine liquid biopsy with diagnostic and stratification value for bladder cancer classification, available through the open app BladdermiRaCan	27
Engineered extracellular vesicles displaying bi-specific T-cell engagers for targeted therapy of B-cell malignancies	27
CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy	26
A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia	26
CRISPR/Cas9 technology for advancements in cancer immunotherapy: from uncovering regulatory mechanisms to therapeutic applications	26
Combinatorial functionomics identifies HDAC6-dependent molecular vulnerability of radioresistant head and neck cancer	26
Immunotherapy in chronic lymphocytic leukemia: advances and challenges	25
Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia	25
The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment	25
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting	25
Incidence, mortality, and risk factors of bladder, kidney, prostate and testicular cancers in China and comparisons with the United States, the United Kingdom, Japan, and the Republic of Korea: an up-	24
Sarcosine sensitizes lung adenocarcinoma to chemotherapy by dual activation of ferroptosis via PDK4/PDHA1 signaling and NMDAR-mediated iron export	24
Efficacy of melflufen in multiple myeloma with mutated or deleted TP53	24
Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis	24
Obesity- and tumor-derived signals drive cancer-associated state transitions in breast mesenchymal stromal/stem cells reprogrammed by IL1RA or JAK inhibition	24
DLC1 deficiency at diagnosis predicts poor prognosis in acute myeloid leukemia	24
The roles of tissue resident macrophages in health and cancer	23
Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting	23
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma	22
Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer	22
Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance	22
Crosstalk between ferroptosis and extracellular vesicles in cancer: from interaction to clinical application	21
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates	21
Epigenetic and post-translational regulatory networks of ferroptosis in the tumor immune microenvironment	21
Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies	20
An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo	20
Correction: New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	20
Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA	20
Adefovir dipivoxil inhibits APL progression through degradation of the oncoprotein PML-RARA	20
Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolution	20
Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults	19
Molecular background of Philadelphia chromosome dependent enhancement of cellular growth and tyrosine kinase inhibitor sensitivity	19
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma	19
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies	19
In-depth insight into tumor-infiltrating stromal cells linked to tertiary lymphoid structures and their prospective function in cancer immunotherapy	19
Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies	19
Bladder cancer subtypes exhibit limited plasticity across different microenvironments and in metastases	19
In vivo CAR-T engineering: insights from the 2025 ASH annual meeting	19
Biomechanics in the tumor microenvironment: from biological functions to potential clinical applications	19
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities	19